What is new in the 2024 Chinese guidelines for fatty liver disease?

What is new in the 2024 Chinese guidelines for fatty liver disease?

Saved in:

Bibliographic Details
Main Authors:	Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2025-07-01
Series:	Clinical and Molecular Hepatology
Subjects:	metabolic dysfunction-associated steatotic liver disease obesity metabolic syndrome alcohol-related liver disease china
Online Access:	http://e-cmh.org/upload/pdf/cmh-2024-1165.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The evolution of international definitions of fatty liver disease and insights into the working definition and features of the 2024 Chinese guideline
by: Li CHEN, et al.
Published: (2025-06-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S.
by: Shyam Patel, et al.
Published: (2025-01-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
by: Yangyue Zhang, et al.
Published: (2025-01-01)

Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
by: Yu-Ming Cheng, et al.
Published: (2025-04-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
by: Woo-Young Shin, et al.
Published: (2025-04-01)

Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025
by: Jennifer Panganiban, et al.
Published: (2025-06-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
by: Xianhua Mao, et al.
Published: (2025-07-01)

Role of waist circumference, body mass index and high-sensitivity C-reactive protein in pediatric steatotic liver disease: A cross-sectional study
by: Qiaoling Wu, et al.
Published: (2025-01-01)

Association between alcohol consumption and hepatic fibrosis in Chinese adult males with metabolic dysfunction-associated steatotic liver disease
by: Mao Li, et al.
Published: (2025-04-01)

Associations between circulating amino acids and metabolic dysfunction‐associated steatotic liver disease in individuals living with severe obesity
by: Ina Maltais‐Payette, et al.
Published: (2025-02-01)

Cirrhosis epidemiology in Denmark 1998–2022, and 2030 forecast
by: Linda Skibsted Kornerup, et al.
Published: (2025-05-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
by: Jaehyun Bae, et al.
Published: (2024-11-01)

Circulating angiopoietin-like protein 8 (ANGPTL8) and steatotic liver disease related to metabolic dysfunction: an updated systematic review and meta-analysis
by: Farah Abdelhameed, et al.
Published: (2025-04-01)

Non-alcoholic fatty liver disease and the gut microbiota in adolescents: is there a relationship?
by: Doaa El Amrousy, et al.
Published: (2024-11-01)

From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
by: Bruno Basil, et al.
Published: (2024-12-01)

Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease
by: Wenhao Wu, et al.
Published: (2025-07-01)

Advances in non-invasive diagnosis of metabolic dysfunction-associated fatty liver disease
by: WANG Ziqian, et al.
Published: (2024-07-01)

Serum Irisin, Myostatin, and Myonectin Correlate with Metabolic Health Markers, Liver Disease Progression, and Blood Pressure in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Hypertension
by: Anna F. Sheptulina, et al.
Published: (2024-10-01)

Gut microbiota in liver diseases: initiation, development and therapy
by: Jian-Xiu Yu, et al.
Published: (2025-06-01)

Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review
by: Francisco Aguirre, et al.
Published: (2025-07-01)

Burden of disease and risk factors for primary liver cancer by etiology in the United States, 1990-2021: Results from the Global Burden of Disease study, 2021
by: Duanyu Wang, et al.
Published: (2025-07-01)

Liver fibrosis progression analyzed with AI predicts renal decline
by: Dan-Qin Sun, et al.
Published: (2025-05-01)

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose
by: Satoshi Shinozaki, et al.
Published: (2025-02-01)

Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease
by: Pingping Jin, et al.
Published: (2025-07-01)

Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
by: Zhifeng Gao, et al.
Published: (2025-01-01)

New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile
by: Maria Spencer-Sandino, et al.
Published: (2025-07-01)

Association between periodontitis and mortality in participants with metabolic dysfunction-associated steatotic liver disease: results from NHANES
by: Zhaofu Zhang, et al.
Published: (2025-04-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Associated Liver Disease: Liver DNA Methylation Analysis—A Systematic Review
by: Daniela Stols-Gonçalves, et al.
Published: (2024-11-01)

Dietary characteristics associated with the risk of non‐alcoholic fatty liver disease and metabolic dysfunction‐associated steatotic liver disease in non‐obese Japanese participants: A cross‐sectional study
by: Hirokazu Taniguchi, et al.
Published: (2024-05-01)

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Yeo-Wool Kang, et al.
Published: (2024-11-01)

Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups
by: Tatsuya Fukuda, et al.
Published: (2025-06-01)

Inhibiting Ferroptosis Prevents the Progression of Steatotic Liver Disease in Obese Mice
by: Gi Cheol Park, et al.
Published: (2024-10-01)

Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review
by: Prajith Raj Ramesh, et al.
Published: (2024-12-01)

Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
by: Umasankari S., et al.
Published: (2024-12-01)

Impact of steatotic liver disease categories on atrial fibrillation in type 2 diabetes: a nationwide study
by: So Hyun Cho, et al.
Published: (2025-04-01)

Comprehensive Analysis of Differentially Expressed Profiles of mRNA 5-Methylcytosine Modification in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Yueying Yang, et al.
Published: (2025-04-01)